Biosimilars: Breaking Down Barriers to Patient Access (REMS)

Since it was created in 2007, the Food & Drug Administration’s (FDA’s) Risk Evaluation and Mitigation Strategies (REMS) has been an important tool for patient safety by ensuring that the benefits of a drug or biological product outweigh its safety risks…

ORGANIZATION:

RESOURCE TYPE:
INFOGRAPHIC